NDAINJECTIONINJECTABLEPriority Review
Approved
Feb 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
R-GENE 10 (arginine hydrochloride) by Pfizer is clinical pharmacology intravenous infusion of r-gene 10 often induces a pronounced rise in the plasma level of human growth hormone (hgh) in subjects with intact pituitary function. First approved in 1973.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
R-GENE 10 (arginine hydrochloride) is an intravenous diagnostic agent that stimulates human growth hormone (HGH) secretion in patients with intact pituitary function. It is used as a provocative test to assess pituitary HGH reserve and differentiate between normal and pituitary-deficient states. L-arginine works by triggering GH release from the anterior pituitary gland, with peak plasma levels typically appearing 10–30 ng/mL in normal subjects versus 0–10 ng/mL in pituitary-deficient patients.
LOE Approaching
As a legacy diagnostic agent approaching loss of exclusivity with minimal modern market presence, career growth is limited and team size is likely contracted.
Mechanism of Action
CLINICAL PHARMACOLOGY Intravenous infusion of R-Gene 10 often induces a pronounced rise in the plasma level of human growth hormone (HGH) in subjects with intact pituitary function. This rise is usually diminished or absent in patients with impairment of this function. Expected Plasma Levels of HGH…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and a legacy product in LOE phase, R-GENE 10 offers minimal career opportunity for advancement or skill diversification. This role would suit only a specialist seeking niche diagnostic expertise or a terminal assignment in a declining portfolio.
Worked on R-GENE 10 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.